110995 ⎘
ssRNA viruses negative-sense; Details; Paramyxoviridae; Pneumovirus, e.g. human respiratory syncytial virus Demonstrated effect
TRUNCATED RESPIRATORY SYNCYTIAL VIRUS F PROTEIN AND USE THEREOF
#2METHOD OF VACCINATION WITH AN ATTENUATED RSV VACCINE FORMULATION
#3ADENOVIRAL VECTOR VACCINE AGAINST RESPIRATORY SYNCYTIAL VIRUS, AND PREPARATION METHOD THEREFOR AND USE THEREOF
#4VACCINATION IN NEWBORNS AND INFANTS
#5VACCINATION IN NEWBORNS AND INFANTS
#6RSV F Protein Mutants
#7VIRAL PROTEINS AND NANOSTRUCTURES AND USES THEREOF
#8MULTIVALENT VACCINE FOR PARAMYXOVIRUSES AND USES THEREOF
#9CONFORMATIONALLY STABILIZED RSV PRE-FUSION F PROTEINS
#10RECOMBINANT HUMAN/BOVINE PARAINFLUENZA VIRUS 3 (B/HPIV3) EXPRESSING A CHIMERIC RSV/PIV3 F PROTEIN AND USES THEREOF
#11MODIFIED VIRUS-LIKE PARTICLES OF BACTERIOPHAGE AP205
#12METHOD OF ELICITING AN IMMUNE RESPONSE AGAINST RESPIRATORY SYNCYTIAL VIRUS
#13METHODS FOR IMMUNIZING PRE-IMMUNE SUBJECTS AGAINST RESPIRATORY SYNCYTIAL VIRUS (RSV)
#14METHOD OF TARGETING ONCOLYTIC VIRUSES TO TUMORS
#15MODIFIED RSV F PROTEINS AND METHODS OF THEIR USE
#16Recombinant human parainfluenza virus type 1 expressing a chimeric RSV/HPIV1 f protein and uses thereof
#17LIVE ATTENUATED RESPIRATORY SYNCYTIAL VIRUS
#18VACCINATION IN NEWBORNS AND INFANTS
#19RSV F Protein Mutants
#20MUTANT RSV F PROTEIN AND USE THEREOF
#21Conformationally stabilized RSV pre-fusion F proteins
#22FcRn-targeted mucosal vaccination against RSV
#23Methods of using low dose volume B-cell epitope compositions for inducing an antibody immune response in human subjects
#24Recombinant RSV live vaccine strain and the preparing method thereof
#25RSV vaccines and methods of production and use thereof
#26Vaccine against RSV
#27Methods for immunizing pre-immune subjects against respiratory syncytial virus (RSV)
#28Recombinant chimeric bovine/human parainfluenza virus 3 expressing rsv g and its use
#29Antigenic Multimeric Respiratory Syncytial Virus Polypeptides
#30CHIMPANZEE ADENOVIRUS CONSTRUCTS WITH LYSSAVIRUS ANTIGENS
#31RESPIRATORY SYNCYTIAL VIRUS RECOMBINANT F PROTEIN AND VACCINE COMPOSITION CONTAINING SAME
#32METHODS FOR INACTIVATING AND STORING RESPIRATORY SYNCYTIAL VIRUS
#33CHIMPANZEE ADENOVIRUS CONSTRUCTS WITH LYSSAVIRUS ANTIGENS
#34Recombinant chimeric bovine/human parainfluenza virus 3 expressing RSV G and its use
#35Immune composition comprising respiratory syncytial virus (RSV) G polypeptide
#36VACCINATION IN NEWBORNS AND INFANTS
#37RSV vaccines and methods of production and use thereof
#38Conformationally stabilized RSV pre-fusion F proteins
#39Vaccine against RSV
#40Immunogenic RSV polypeptides
#41Vaccination in newborns and infants
#42Recombinant human/bovine parainfluenza virus 1 (HPIV1) expressing a chimeric RSV/HPIV1 F protein and uses thereof
#43Recombinant modified vaccinia virus ankara (MVA) respiratory syncytial virus (RSV) vaccine
#44Methods for immunizing pre-immune subjects against respiratory syncytial virus (RSV)
#45Modified RSV F proteins and methods of their use
#46Recombinant prefusion RSV F proteins and uses thereof
#47Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
#48Affenadenovirus (gorilla) or adenoviral vectors and methods of use
#49Nanostructures comprising cobalt porphyrin-phospholipid conjugates and polyhistidine-tags
#50Methods of using low dose volume B-cell epitope compositions for inducing an antibody immune response in human subjects
#51RSV vaccines and methods of production and use thereof
#52Method of targeting oncolytic viruses to tumors
#53Vaccination in newborns and infants
#54Modified RSV F proteins and methods of their use
#55RSV F protein mutants
#56Vaccine against RSV
#57Recombinant modified vaccinia virus ankara (MVA) respiratory syncytial virus (RSV) vaccine
#58Cationic oil-in-water emulsions
#59RESPIRATORY SYNCYTIAL VIRUS VACCINE
#60FcRn-targeted mucosal vaccination against RSV
#61Vaccination in newborns and infants
#62Human respiratory syncytial virus (HRSV) virus-like particles (VLPS) based vaccine
#63Method of vaccination with an attenuated RSV vaccine formulation
#64Recombinant human/bovine parainfluenza virus 3 (B/HPIV3) expressing a chimeric RSV/BPIV3 F protein and uses thereof
#65RSV F protein mutants
#66Immunogenic RSV polypeptides
#67Recombinant modified vaccinia virus Ankara (MVA) Respiratory Syncytial Virus (RSV) vaccine
#68Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
#69Affenadenovirus (gorilla) or adenoviral vectors and methods of use
#70Cationic oil-in-water emulsions
#71Vaccination in newborns and infants
#72RSV F protein mutants
#73Recombinant modified vaccinia virus ankara (MVA) respiratory syncytial virus (RSV) vaccine
#74Respiratory syncytial virus vaccine
#75Recombinant respiratory syncytial virus G protein fragments
#76Compositions and methods comprising hydrocarbon-stapled polypeptides
#77Anti-human Respiratory Syncytial Virus (RSV) antibodies and methods of use
#78Modified RSV F proteins and methods of their use
#79Modified RSV F proteins and methods of their use
#80Modified RSV F proteins and methods of their use
#81SELF-ASSEMBLED NANOPARTICLE VACCINES
#82Epitope-scaffold immunogens against respiratory syncytial virus (RSV)
#83Stabilized antiviral fusion helices
#84COMBINED ANTIGEN AND DNA VACCINE FOR PREVENTING AND TREATING RSV INFECTION
#85Anti-human respiratory syncytial virus (RSV) antibodies and methods of use
#86Modified RSV F proteins and methods of their use
#87Anti-human respiratory syncytial virus (RSV) antibodies and methods of use
#88Compositions and methods for the treatment of viral infections
#89Deletion mutants of flagellin and methods of use
#90Virus-like particles as vaccines for paramyxovirus
#91Modified RSV F proteins and methods of their use
#92Virus-like particles as vaccines for paramyxovirus